top of page
WHAT WE DO?
Influenza-Based Viral Vector System for Pandemic and Epidemic Respiratory Vaccines
The influenza-based viral vector vaccine platform is one novel strategy with a multi-purpose for the development of an intranasal vaccine for influenza, COVID-19, and other future respiratory viral diseases.
CORE TECHNOLOGY
New Vaccine within 3 weeks
Cutting-Edge Viral Vector Vaccine Platform
Technology contributor, a spinoff from Centre for Virology, Vaccine and Therapeutics (InnoHK), has a vaccine platform that has completed proof of concept for influenza and COVID -19. Antigen of any highly contagious virus can be inserted into this platform to make a new vaccine within 3 weeks, the process is cell-based using attenuated virus technology and require containment.
bottom of page